JP5536912B2 - Platelet aggregation inhibitor - Google Patents

Platelet aggregation inhibitor Download PDF

Info

Publication number
JP5536912B2
JP5536912B2 JP2013002209A JP2013002209A JP5536912B2 JP 5536912 B2 JP5536912 B2 JP 5536912B2 JP 2013002209 A JP2013002209 A JP 2013002209A JP 2013002209 A JP2013002209 A JP 2013002209A JP 5536912 B2 JP5536912 B2 JP 5536912B2
Authority
JP
Japan
Prior art keywords
platelet aggregation
aggregation inhibitor
present
group
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013002209A
Other languages
Japanese (ja)
Other versions
JP2013067658A (en
Inventor
美穂子 比留間
英司 高井
康次郎 森光
紀久枝 久保田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Soda Aromatic Co Ltd
Original Assignee
Soda Aromatic Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Soda Aromatic Co Ltd filed Critical Soda Aromatic Co Ltd
Priority to JP2013002209A priority Critical patent/JP5536912B2/en
Publication of JP2013067658A publication Critical patent/JP2013067658A/en
Application granted granted Critical
Publication of JP5536912B2 publication Critical patent/JP5536912B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Description

本発明は、血小板凝集抑制剤に関する。さらには、血小板の凝集を抑制することによる血流改善剤、抗血栓剤などに関する。   The present invention relates to a platelet aggregation inhibitor. Furthermore, the present invention relates to a blood flow improving agent, an antithrombotic agent and the like by suppressing platelet aggregation.

各種プロスタグランジン類やトロンボキサンなどは、アラキドン酸を出発物質として生合成されることが知られている。これらアラキドン酸代謝産物は、生体内の各種調節機構に関与していることが知られている一方、炎症や血栓の生成にも深く関与していることも知られている。また、近年、一般に血液の流動性やアレルギー性のものを含む各種炎症の改善などに対する関心が高まっており、このアラキドン酸の代謝経路を制御することによって、様々な症状を緩和する方法が注目されている。たとえば、キノリルメトキシフェニル酢酸やその誘導体によるアラキドン酸代謝の抑制(特許文献1)、桑白皮、甘草の抽出物またはその成分によるアラキドン酸代謝異常の治療(特許文献2)、モルギンまたはその誘導体によるアラキドン酸代謝を阻害する方法(特許文献3)、カンキツ果皮抽出物によりアラキドン酸代謝酵素を阻害する方法(特許文献4)などが提案されている。
また、カプサイシンやトウガラシ抽出物が血流促進効果を有することが知られているが、これらは刺激が強いため投与方法や投与量に制限があるなど使用方法や用途が限られている。
Various prostaglandins and thromboxanes are known to be biosynthesized using arachidonic acid as a starting material. While these arachidonic acid metabolites are known to be involved in various regulatory mechanisms in the living body, it is also known to be deeply involved in inflammation and thrombus generation. In recent years, there has been an increasing interest in improving various inflammations, including blood fluidity and allergic properties, and attention has been focused on methods for alleviating various symptoms by controlling the metabolic pathway of arachidonic acid. ing. For example, inhibition of arachidonic acid metabolism by quinolylmethoxyphenylacetic acid and its derivatives (Patent Document 1), treatment of abnormal arachidonic acid metabolism by mulberry bark, licorice extract or its components (Patent Document 2), morgin or its derivatives There have been proposed a method for inhibiting arachidonic acid metabolism (Patent Document 3), a method for inhibiting arachidonic acid metabolizing enzyme with citrus peel extract (Patent Document 4), and the like.
In addition, capsaicin and pepper extract are known to have a blood flow promoting effect, but their use is limited because of their strong irritation, and there are restrictions on the administration method and dose.

特開平06−157463号公報Japanese Patent Laid-Open No. 06-157463 特開平07−017859号公報Japanese Patent Laid-Open No. 07-017859 特開平08−113536号公報Japanese Patent Laid-Open No. 08-113536 特開平08−245412号公報Japanese Patent Laid-Open No. 08-245412

本発明者は、血小板の凝集が原因で引き起こされる様々な生体への悪影響の症状を軽減し、もしくは予防することができる、新規な血小板凝集抑制剤を提供すること、特に、より簡便に入手できるとともに、大量生産が容易に実現可能な血小板凝集抑制剤を提供することを目的とする。   The present inventor provides a novel platelet aggregation inhibitor that can reduce or prevent various symptoms of adverse effects on living bodies caused by aggregation of platelets, and is particularly easily available. Another object is to provide a platelet aggregation inhibitor that can be easily mass-produced.

本発明は、下記式

Figure 0005536912

(式中は、水酸基および/または炭素数1〜3のアルキル基が結合してもよいフェニル基またはメチルフェニル基またはエチルフェニル基、水酸基で置換されてもよい炭素数1〜10の直鎖まはた分岐鎖もしくは環を形成してもよい飽和または不飽和の炭素鎖を示す)で示されるチグリン酸エステル類から選ばれる少なくとも1つをを有効成分として含有する血小板凝集抑制剤である。また、本発明はさらに、該血小板凝集抑制剤を有効成分とする、血流改善剤または抗血栓剤である。 The present invention has the following formula:
Figure 0005536912

(In the formula, R is a phenyl group or a methylphenyl group or an ethylphenyl group to which a hydroxyl group and / or an alkyl group having 1 to 3 carbon atoms may be bonded, or a linear chain having 1 to 10 carbon atoms that may be substituted with a hydroxyl group. Or a platelet aggregation inhibitor containing, as an active ingredient, at least one selected from tiglic acid esters represented by a saturated or unsaturated carbon chain that may form a branched chain or a ring. The present invention is further a blood flow improving agent or antithrombotic agent comprising the platelet aggregation inhibitor as an active ingredient.

本発明によれば、血小板の凝集を抑制し、血流促進、血栓予防の予防、緩和の効果を得ることができる。   According to the present invention, platelet aggregation can be suppressed, and blood flow promotion, thrombus prevention prevention, and relaxation effects can be obtained.

本発明の、下記式

Figure 0005536912

(式中は、水酸基および/または炭素数1〜3のアルキル基が結合してもよいフェニル基またはメチルフェニル基またはエチルフェニル基、水酸基で置換されてもよい炭素数1〜10の直鎖まはた分岐鎖もしくは環を形成してもよい飽和または不飽和の炭素鎖を示す)で示されるチグリン酸エステル類は一般に香料化合物として市販されており容易に入手することができ、いずれも公知の方法によって製造することもできる。 The following formula of the present invention
Figure 0005536912

(In the formula, R is a phenyl group or a methylphenyl group or an ethylphenyl group to which a hydroxyl group and / or an alkyl group having 1 to 3 carbon atoms may be bonded, or a linear chain having 1 to 10 carbon atoms that may be substituted with a hydroxyl group. Or a glycerin ester represented by a saturated or unsaturated carbon chain that may form a branched chain or a ring) is generally commercially available as a perfume compound and can be easily obtained. It can also be produced by this method.

本発明の血小板凝集抑制剤は、用途に応じて、エタノール、水、プロピレングリコール、グリセリン、食用油脂またはそれらの混合溶液などの溶剤、医薬や食品に適用可能な塩類、糖、糖アルコール、賦形剤、可溶化剤、乳化剤、分散剤、安定化剤、抗酸化剤、色素、香料などを適宜配合することができる。   The platelet aggregation inhibitor of the present invention is a solvent such as ethanol, water, propylene glycol, glycerin, edible oil or fat, or a mixed solution thereof, salts applicable to pharmaceuticals and foods, sugars, sugar alcohols, and excipients, depending on applications. An agent, a solubilizer, an emulsifier, a dispersant, a stabilizer, an antioxidant, a pigment, a fragrance, and the like can be appropriately blended.

本発明の血小板凝集抑制剤において、前記の化合物群の含有量は特に限定されないが、0.0001〜100質量%であることが好ましい。   In the platelet aggregation inhibitor of the present invention, the content of the compound group is not particularly limited, but is preferably 0.0001 to 100% by mass.

本発明の血小板凝集抑制剤の形態は、特に限定されない。例えば、液状のままでもよく、公知の方法によって乳化、分散、粉末化するなど、用途に応じて適宜選択することができる。   The form of the platelet aggregation inhibitor of the present invention is not particularly limited. For example, it may remain in a liquid state, and can be appropriately selected depending on the application, such as emulsification, dispersion, and powderization by a known method.

本発明の血小板凝集抑制剤は、ビタミン、ミネラル、アミノ酸、などの栄養強化剤、抗酸化剤、抗菌剤、その他の薬剤などと配合して使用することができる。   The platelet aggregation inhibitor of the present invention can be used in combination with a nutrient enhancer such as vitamins, minerals, amino acids, antioxidants, antibacterial agents, and other agents.

本発明の血小板凝集抑制剤を、医薬品もしくは医薬部外品として製剤化する場合は、必要に応じて安定化剤、着色剤、嬌味剤、香料、賦形剤、溶剤、界面活性剤、乳化剤、保存剤、溶解補助剤、等張化剤、緩衝剤、保湿剤、結合剤、被覆剤、潤沢剤、崩壊剤、経皮吸収剤などを加え、液剤、粉剤、散剤、顆粒剤、錠剤、糖衣剤、カプセル剤、懸濁剤、座剤、浴剤、軟膏、クリーム、ゲル、貼付剤、注射液、点眼剤など任意の剤形を選択することができるが、本発明の血小板凝集抑制剤は、その緩和な作用から健康補助の目的に特に適していることから、特に経口摂取に適した剤形が好ましい。   When formulating the platelet aggregation inhibitor of the present invention as a pharmaceutical product or quasi-drug, a stabilizer, a coloring agent, a flavoring agent, a fragrance, an excipient, a solvent, a surfactant, an emulsifier, as necessary. , Preservatives, solubilizers, tonicity agents, buffers, moisturizers, binders, coatings, lubricants, disintegrants, transdermal absorption agents, liquids, powders, powders, granules, tablets, Any dosage form such as sugar coating, capsule, suspension, suppository, bath preparation, ointment, cream, gel, patch, injection solution, eye drop can be selected, and the platelet aggregation inhibitor of the present invention Is particularly suitable for the purpose of health support due to its mild action, and thus a dosage form particularly suitable for oral intake is preferred.

本発明の血小板凝集抑制剤に用いる有効成分は従来から主に香料として使用されている化合物であるため、飲食品や香粧品などに添加することができる。例えば、乳飲料、清涼飲料、嗜好飲料、アルコール飲料などの飲料、チョコレート、キャンディ、錠菓、ガム、スナック菓子、クッキー、ケーキ、その他焼き菓子などの菓子類、氷菓、アイスクリームなどの冷菓類、即席麺類、レトルト食品、冷凍食品などの調理食品、調味料、栄養補助食品などの食品類に添加することで、血流促進、血栓予防の低減など健康維持の機能を付加することができる。   Since the active ingredient used in the platelet aggregation inhibitor of the present invention is a compound that has been used mainly as a fragrance, it can be added to foods and drinks, cosmetics, and the like. For example, beverages such as milk drinks, soft drinks, taste drinks, alcoholic drinks, chocolate, candy, tablet confectionery, gum, snack confectionery, cookies, cakes, other baked confectionery, frozen confectionery such as ice confectionery, ice cream, and instant By adding to cooked foods such as noodles, retort foods, frozen foods, foods such as seasonings and dietary supplements, health maintenance functions such as promoting blood flow and reducing thrombus prevention can be added.

前記飲食品には、血流改善効果を有する旨の表示を付すことができる。本発明における表示の具体的な態様としては、飲食品の包装、容器、店頭表示媒体、広告媒体などが挙げられる。   The said food / beverage products can be attached | subjected with the display of having the blood-flow improvement effect. Specific embodiments of the display in the present invention include food and beverage packaging, containers, storefront display media, advertising media, and the like.

本発明の血小板凝集抑制剤を飲食品に添加する場合、特に添加量の制限はないが、0.001〜5質量%であることが好ましい。   When adding the platelet aggregation inhibitor of this invention to food-drinks, there is no restriction | limiting in particular in addition amount, However, It is preferable that it is 0.001-5 mass%.

本発明の血小板凝集抑制剤を飲食品に添加する方法は、特に制限はないが必要に応じて、乳化剤、分散剤、安定化剤などを加えることもできる。   The method for adding the platelet aggregation inhibitor of the present invention to a food or drink is not particularly limited, but an emulsifier, a dispersant, a stabilizer and the like can be added as necessary.

本発明の血小板凝集抑制剤を飲食品に添加する場合は、ビタミン、ミネラル、アミノ酸などの栄養強化剤、抗酸化剤、抗菌剤、食物繊維、本発明の血小板凝集抑制剤以外による血流促進剤、抗血栓剤など他の機能性成分を本発明のアラキドン酸代謝抑制剤の機能を阻害しない範囲で併用することもできる。   When the platelet aggregation inhibitor of the present invention is added to a food or drink, nutrient enhancers such as vitamins, minerals, amino acids, antioxidants, antibacterial agents, dietary fiber, blood flow promoters other than the platelet aggregation inhibitor of the present invention In addition, other functional components such as an antithrombotic agent can be used in combination as long as the function of the arachidonic acid metabolism inhibitor of the present invention is not inhibited.

本発明の血小板凝集抑制剤は、香水、化粧水、ファンデーション、口紅、クリーム、ローション、乳液、ジェル、パック、日焼け止め、サンオイルなどの化粧品類、石鹸、ボディーシャンプー、洗顔料などの身体洗浄剤、シャンプー、リンス、ヘアートリートメント剤、整髪料、染毛剤、パーマネント剤、養毛剤などの毛髪化粧料、シェービングフォーム、シェービングクリーム、アフターシェーブローション、歯磨き、洗口剤、粉末洗剤、液体洗剤、漂白剤、柔軟剤、浴剤、衛生用品、避妊具などの香粧品類に添加することができる。   The platelet aggregation inhibitor of the present invention is a body cleansing agent such as perfume, lotion, foundation, lipstick, cream, lotion, emulsion, gel, pack, sunscreen, sun oil, soap, body shampoo, face wash Shampoo, rinse, hair treatment agent, hair conditioner, hair dye, permanent agent, hair cosmetics such as hair nourishing agent, shaving foam, shaving cream, after shave lotion, toothpaste, mouthwash, powder detergent, liquid detergent, bleach, It can be added to cosmetics such as softeners, bath preparations, hygiene products and contraceptives.

本発明の血小板凝集抑制剤を香粧品類に添加する場合、特に添加量の制限はないが、0.001〜15質量%であることが好ましい。   When adding the platelet aggregation inhibitor of this invention to cosmetics, there is no restriction | limiting in particular in addition amount, However, It is preferable that it is 0.001-15 mass%.

本発明の血小板凝集抑制剤を香粧品に添加する方法は特に限定されないが、必要に応じて乳化剤、分散剤、安定化剤、賦形剤などを加えることもできる。   The method for adding the platelet aggregation inhibitor of the present invention to a cosmetic product is not particularly limited, but an emulsifier, a dispersant, a stabilizer, an excipient and the like can be added as necessary.

本発明の血小板凝集抑制剤を香粧品に添加する場合は、抗酸化剤、ビタミン、ミネラル、アミノ酸、保湿剤、紫外線吸収剤、抗菌剤、抗かび剤、メラニン生成抑制剤、養毛剤、冷感剤、温感剤、吸収促進剤、本発明の血小板凝集抑制剤抑制以外による血流促進剤、抗血栓剤、抗アレルギー剤など他の機能性物質を本発明の血小板凝集抑制剤の機能を阻害しない範囲で併用することもできる。   When adding the platelet aggregation inhibitor of the present invention to cosmetics, antioxidants, vitamins, minerals, amino acids, moisturizers, ultraviolet absorbers, antibacterial agents, antifungal agents, melanin production inhibitors, hair nourishing agents, cooling sensation agents Other functional substances such as warming agents, absorption promoters, blood flow promoters, antithrombotic agents, and antiallergic agents other than those inhibiting the platelet aggregation inhibitor of the present invention do not inhibit the functions of the platelet aggregation inhibitor of the present invention. It can also be used in combination.

(試験方法)
人の血液に10%濃度になるように3.8%クエン酸ナトリウム液を加え、この血液を1000rpmで10分間遠心分離し、上層部を採取、これを多血小板血漿(PRP)とした。
(Test method)
A 3.8% sodium citrate solution was added to human blood to a concentration of 10%, this blood was centrifuged at 1000 rpm for 10 minutes, and the upper layer was collected, and this was used as platelet-rich plasma (PRP).

具体的な測定方法としては、被験物質を測定容器に入れ、さらにPRP270μlを加えたものを測定装置に設置し、37℃で撹拌しながら30秒間インキュベートした。続いて、30秒以内に凝集惹起剤として0.2Mに調整したアラキドン酸のメタノール溶液を2μL加え、測定容器設置から7分後までの凝集率を測定した。   As a specific measurement method, a test substance was placed in a measurement container, and further 270 μl of PRP was added to the measurement apparatus, and incubated at 37 ° C. with stirring for 30 seconds. Subsequently, 2 μL of a methanol solution of arachidonic acid adjusted to 0.2 M was added as an agglutination-inducing agent within 30 seconds, and the agglomeration rate was measured after 7 minutes from installation of the measurement container.

興和株式会社製の血小板凝集能測定装置(コーワPA−20)を使用し、PRPに被験物質を加えず、凝集惹起剤のみを加えて血小板を凝集させたときの値をコントロールとした。   Using a platelet aggregating capacity measuring device (Kowa PA-20) manufactured by Kowa Co., Ltd., the test substance was not added to PRP, but only the aggregation-inducing agent was added and the value when platelets were aggregated was used as a control.

血小板凝集阻害活性は、以下の計算方法により血小板凝集阻害率を求めることで評価した。
(血小板凝集阻害率計算法)
PRP+凝集惹起剤のみを加えたときの最大凝集率をAとする。
被験物質+PRP+アラキドン酸を加えたときの最大凝集率をBとする。
凝集阻害率(%)をCとすると
C=100−B/A×100
Platelet aggregation inhibition activity was evaluated by determining the platelet aggregation inhibition rate by the following calculation method.
(Platelet aggregation inhibition rate calculation method)
A is the maximum aggregation rate when only the PRP + aggregation inducing agent is added.
Let B be the maximum aggregation rate when test substance + PRP + arachidonic acid is added.
When the aggregation inhibition rate (%) is C, C = 100−B / A × 100

(試験結果)
前記試験方法において、被験物質の濃度が2mMとなる量を添加した条件下で血小板凝集阻害活性を測定した。本発明の有効成分の試験結果を表1に示す。また、本発明の有効成分と類似した構造を有し、かつ充分な活性が得られなかったオクタン酸とウンデカン酸を比較例として同じく表1に示す。
(Test results)
In the test method, the platelet aggregation inhibitory activity was measured under the condition that the amount of the test substance was 2 mM. Table 1 shows the test results of the active ingredients of the present invention. Table 1 also shows, as comparative examples, octanoic acid and undecanoic acid that have a structure similar to that of the active ingredient of the present invention and that did not provide sufficient activity.

Figure 0005536912
Figure 0005536912

表1に示すように本発明の化合物には、トウガラシチンキと比較して、同等かそれ以上の活性が確認された。   As shown in Table 1, the compound of the present invention was confirmed to have an activity equal to or higher than that of chili tincture.

以下に本発明の血小板凝集抑制剤の製剤例について、一例を示す。   An example of a formulation example of the platelet aggregation inhibitor of the present invention is shown below.


錠剤配合例(質量比)
──────────────────────
本発明の血小板凝集抑制剤 5.0
6%HPC乳糖 80.0
ステアリン酸マグネシウム 4.0
バレイショデンプン 6.0
──────────────────────

Tablet formulation example (mass ratio)
──────────────────────
Platelet aggregation inhibitor of the present invention 5.0
6% HPC lactose 80.0
Magnesium stearate 4.0
Potato starch 6.0
──────────────────────


軟膏剤配合例(質量比)
─────────────────────────
白色ワセリン 20.0
ステアリルアルコール 22.0
プロピレングリコール 12.0
ラウリル硫酸ナトリウム 1.5
パラベン 0.2
本発明の血小板凝集抑制剤 5.0
精製水 39.3
─────────────────────────

Ointment formulation example (mass ratio)
─────────────────────────
White petrolatum 20.0
Stearyl alcohol 22.0
Propylene glycol 12.0
Sodium lauryl sulfate 1.5
Paraben 0.2
Platelet aggregation inhibitor of the present invention 5.0
Purified water 39.3
─────────────────────────


入浴剤配合例(質量比)
――――――――――――――――――――――─
炭酸水素ナトリウム 50.0
硫酸ナトリウム 45.0
本発明の血小板凝集抑制剤 1.3
香料 0.7
色素 3.0
───────────────────────

Bath salt formulation example (mass ratio)
――――――――――――――――――――――――
Sodium bicarbonate 50.0
Sodium sulfate 45.0
Platelet aggregation inhibitor of the present invention 1.3
Fragrance 0.7
Dye 3.0
───────────────────────

以下に本発明の血小板凝集抑制剤の食品への配合例について一例を示す。   An example of a formulation example of the platelet aggregation inhibitor of the present invention in a food is shown below.


アイスクリーム配合例(質量比)
────────────────────────
全脂練乳 10.0
生クリーム 9.4
無塩バター 2.0
脱脂粉乳 3.4
砂糖 12.0
安定剤 0.3
乳化剤 0.2
pH調整剤 0.1
カラメル色素 0.1
本発明の血小板凝集抑制剤 0.01
香料 0.01
水 49.0
────────────────────────

Ice cream formulation example (mass ratio)
────────────────────────
Whole fat condensed milk 10.0
Fresh cream 9.4
Unsalted butter 2.0
Nonfat dry milk 3.4
Sugar 12.0
Stabilizer 0.3
Emulsifier 0.2
pH adjuster 0.1
Caramel pigment 0.1
Platelet aggregation inhibitor of the present invention 0.01
Fragrance 0.01
Water 49.0
────────────────────────


クッキー生地配合例(質量比)
────────────────────────
薄力粉 62.5
全粒粉 37.5
ショートニング 30.0
全卵 30.0
砂糖 20.0
水飴 1.0
脱脂粉乳 5.0
食塩 1.2
食用油脂 30.0
重炭酸ソーダ 1.0
重炭酸アンモニウム 1.0
本発明の血小板凝集抑制剤 0.1
香料 0.3
水 11.0
────────────────────────

Cookie dough formulation example (mass ratio)
────────────────────────
Soft flour 62.5
Whole grain 37.5
Shortening 30.0
Whole egg 30.0
Sugar 20.0
Minamata 1.0
Nonfat dry milk 5.0
Salt 1.2
Edible oils and fats 30.0
Sodium bicarbonate 1.0
Ammonium bicarbonate 1.0
Platelet aggregation inhibitor of the present invention 0.1
Fragrance 0.3
Water 11.0
────────────────────────


チョコレート配合例(質量比)
─────────────────────────
カカオ液 12.0
カカオバター 24.0
ショ糖 33.0
フルクリームミルクパウダー 19.0
スキムミルクパウダー 11.4
レシチン 0.5
本発明の血小板凝集抑制剤 0.01
香料 0.1
─────────────────────────

Chocolate formulation example (mass ratio)
─────────────────────────
Cocoa liquor 12.0
Cocoa butter 24.0
Sucrose 33.0
Full cream milk powder 19.0
Skim milk powder 11.4
Lecithin 0.5
Platelet aggregation inhibitor of the present invention 0.01
Fragrance 0.1
─────────────────────────


ノンオイルドレッシング配合例(質量比)
─────────────────────────
濃口醤油 10.0
醸造酢 6.0
リンゴ酢 5.0
レモン果汁 4.0
液糖 7.0
食塩 2.0
調味料 7.0
香料 0.2
本発明の血小板凝集抑制剤 0.01
水 50.0
─────────────────────────

Non-oil dressing formulation example (mass ratio)
─────────────────────────
Dark soy sauce 10.0
Brewing vinegar 6.0
Apple cider vinegar 5.0
Lemon juice 4.0
Liquid sugar 7.0
Salt 2.0
Seasoning 7.0
Fragrance 0.2
Platelet aggregation inhibitor of the present invention 0.01
Water 50.0
─────────────────────────


飲料配合例(質量比)
――――――――――――――――――――――───
果糖ぶどう糖液糖 60.0
アップル透明果汁 4.3
クエン酸 2.3
クエン酸三ナトリウム 0.8
アスコルビン酸 0.2
スクラロース 0.03
アセスルファムカリウム 0.02
香料 0.99
本発明の血小板凝集抑制剤 0.1
水 31.0
――――――――――――――――――――――───

Beverage formulation example (mass ratio)
―――――――――――――――――――――――― ──
Fructose glucose liquid sugar 60.0
Apple transparent fruit juice 4.3
Citric acid 2.3
Trisodium citrate 0.8
Ascorbic acid 0.2
Sucralose 0.03
Acesulfame potassium 0.02
Perfume 0.99
Platelet aggregation inhibitor of the present invention 0.1
Water 31.0
―――――――――――――――――――――――― ──


チューインガム配合例(質量比)
――――――――――――――――――――――─
ガムベース 20.0
砂糖 60.0
ブドウ糖 10.0
水飴 8.0
グリセリン 5.0
香料 0.9
本発明の血小板凝集抑制剤 0.1
───────────────────────

Chewing gum formulation example (mass ratio)
――――――――――――――――――――――――
Gum base 20.0
Sugar 60.0
Glucose 10.0
Minamata 8.0
Glycerin 5.0
Fragrance 0.9
Platelet aggregation inhibitor of the present invention 0.1
───────────────────────

本発明の血小板凝集抑制剤は、香料として使用実績がある化合物であり、刺激性などは極めて小さく、飲食品や香粧品類など幅広く添加することができる。また、本発明の化合物は容易に合成ができるため、大量生産が可能である。   The platelet aggregation inhibitor of the present invention is a compound that has been used as a fragrance and has very little irritation and can be widely added to foods and drinks and cosmetics. Further, since the compound of the present invention can be easily synthesized, it can be mass-produced.

Claims (3)

下記式
Figure 0005536912

(式中Rは、水酸基および/または炭素数1〜3のアルキル基が結合してもよいフェニル基またはメチルフェニル基またはエチルフェニル基、水酸基で置換されてもよい炭素数1〜10の直鎖まはた分岐鎖もしくは環を形成してもよい飽和または不飽和の炭素鎖を示す)で示されるチグリン酸エステル類から選ばれる少なくとも1つをを有効成分として含有する血小板凝集抑制剤。
Following formula
Figure 0005536912

(In the formula, R is a phenyl group or a methylphenyl group or an ethylphenyl group to which a hydroxyl group and / or an alkyl group having 1 to 3 carbon atoms may be bonded, or a linear chain having 1 to 10 carbon atoms that may be substituted with a hydroxyl group. Or a platelet aggregation inhibitor containing, as an active ingredient, at least one selected from tiglic acid esters represented by the following formula: a saturated or unsaturated carbon chain that may form a branched chain or ring.
請求項1に記載の血小板凝集抑制剤を有効成分とする血流改善剤。 A blood flow improving agent comprising the platelet aggregation inhibitor according to claim 1 as an active ingredient. 請求項1に記載の血小板凝集抑制剤を有効成分とする抗血栓剤。 An antithrombotic agent comprising the platelet aggregation inhibitor according to claim 1 as an active ingredient.
JP2013002209A 2013-01-10 2013-01-10 Platelet aggregation inhibitor Expired - Fee Related JP5536912B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013002209A JP5536912B2 (en) 2013-01-10 2013-01-10 Platelet aggregation inhibitor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013002209A JP5536912B2 (en) 2013-01-10 2013-01-10 Platelet aggregation inhibitor

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006186102A Division JP2008013486A (en) 2006-07-05 2006-07-05 Arachidonate metabolism inhibitor

Publications (2)

Publication Number Publication Date
JP2013067658A JP2013067658A (en) 2013-04-18
JP5536912B2 true JP5536912B2 (en) 2014-07-02

Family

ID=48473744

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013002209A Expired - Fee Related JP5536912B2 (en) 2013-01-10 2013-01-10 Platelet aggregation inhibitor

Country Status (1)

Country Link
JP (1) JP5536912B2 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005015686A (en) * 2003-06-27 2005-01-20 Kiyomitsu Kawasaki Fruit-like flavor composition

Also Published As

Publication number Publication date
JP2013067658A (en) 2013-04-18

Similar Documents

Publication Publication Date Title
JP4887499B2 (en) Active oxygen scavenger and moisturizer containing wild watermelon extract
WO2012165406A1 (en) Psychic energizer agent and psychic energizer composition
JP2010053122A (en) Lipid synthesis inhibitor
JP5224234B2 (en) Platelet aggregation inhibitor
JP5582593B2 (en) Platelet aggregation inhibitor
JP5536913B2 (en) Platelet aggregation inhibitor
JP5536912B2 (en) Platelet aggregation inhibitor
JP2008013486A (en) Arachidonate metabolism inhibitor
JP4657778B2 (en) Arachidonic acid metabolism inhibitor
JP4953627B2 (en) Arachidonic acid metabolism inhibitor
JP5224235B2 (en) Calcium antagonist
JP4224593B2 (en) Composition for suppressing fat accumulation comprising wasabi as an active ingredient
JP6456032B2 (en) Sirt1 activator and use of the Sirt1 activator
JP5527736B2 (en) Platelet aggregation inhibitor
JP2013082738A (en) Platelet aggregation inhibitor
JP5626609B2 (en) Calcium antagonist
JP2013082739A (en) Platelet aggregation inhibitor
JP2019520786A (en) Moisturizing composition containing 3-O-galoyl-3,3 ', 5,5', 7-pentahydroxyflavone
JP5507892B2 (en) Active oxygen-induced disorder inhibitor
JP7251036B2 (en) Screening method for skin aging improving agent
JP2023059099A (en) myonectin production promoter
JP2023074268A (en) IL-1α expression inhibitor
JP2013075914A (en) Calcium antagonist
JP4657653B2 (en) Body temperature raising agent
JP5246887B2 (en) Body temperature raising agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140320

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140403

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140424

R150 Certificate of patent or registration of utility model

Ref document number: 5536912

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140424

LAPS Cancellation because of no payment of annual fees